Literature DB >> 17974478

Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases.

Brenda J Marsh1, Mary P Stenzel-Poore.   

Abstract

Toll-like receptors (TLRs) are a family of evolutionarily conserved molecules that directly detect pathogen invasion or tissue damage and initiate a biological response. TLRs can signal through two primary intracellular pathways and as such can induce either immuno-stimulatory or immuno-modulatory molecules. Both sides of this twin-edged sword are being examined for their therapeutic potential in combating neurological disease. The immuno-stimulatory properties of TLRs are being used to generate tumor-specific immune responses to CNS tumors while the immuno-modulatory properties are being used to suppress damaging inflammatory responses to stroke. Recently, a third component of TLR signaling has begun to emerge--that of direct neuroprotection. Hence, the TLRs offer novel targets for the treatment of neurological disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17974478      PMCID: PMC2674015          DOI: 10.1016/j.coph.2007.09.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  40 in total

1.  LPS-induced upregulation of SHIP is essential for endotoxin tolerance.

Authors:  Laura M Sly; Michael J Rauh; Janet Kalesnikoff; Christine H Song; Gerald Krystal
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 2.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

3.  Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats.

Authors:  K Tasaki; C A Ruetzler; T Ohtsuki; D Martin; H Nawashiro; J M Hallenbeck
Journal:  Brain Res       Date:  1997-02-14       Impact factor: 3.252

4.  TNF-alpha pretreatment prevents subsequent activation of cultured brain cells with TNF-alpha and hypoxia via ceramide.

Authors:  I Ginis; U Schweizer; M Brenner; J Liu; N Azzam; M Spatz; J M Hallenbeck
Journal:  Am J Physiol       Date:  1999-05

5.  Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance.

Authors:  Holly L Rosenzweig; Manabu Minami; Nikola S Lessov; Sarah C Coste; Susan L Stevens; David C Henshall; Robert Meller; Roger P Simon; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2007-02-28       Impact factor: 6.200

6.  Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat.

Authors:  Wouter B Veldhuis; Joris W Derksen; Sarah Floris; Peter H Van Der Meide; Helga E De Vries; Janneke Schepers; Ine M P Vos; Christien D Dijkstra; L Jaap Kappelle; Klaas Nicolay; Peter R Bär
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

7.  Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs.

Authors:  Julie K Olson; Stephen D Miller
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

8.  mRNA is an endogenous ligand for Toll-like receptor 3.

Authors:  Katalin Karikó; Houping Ni; John Capodici; Marc Lamphier; Drew Weissman
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

9.  Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice.

Authors:  Holly L Rosenzweig; Nikola S Lessov; David C Henshall; Manabu Minami; Roger P Simon; Mary P Stenzel-Poore
Journal:  Stroke       Date:  2004-09-16       Impact factor: 7.914

10.  Induction of 70-kDa heat shock protein and hsp70 mRNA following transient focal cerebral ischemia in the rat.

Authors:  H Kinouchi; F R Sharp; M P Hill; J Koistinaho; S M Sagar; P H Chan
Journal:  J Cereb Blood Flow Metab       Date:  1993-01       Impact factor: 6.200

View more
  24 in total

Review 1.  Mechanisms of ischemic brain damage.

Authors:  Kristian P Doyle; Roger P Simon; Mary P Stenzel-Poore
Journal:  Neuropharmacology       Date:  2008-01-25       Impact factor: 5.250

Review 2.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 3.  The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases.

Authors:  Xiao-Jing Zhang; Ding-Sheng Jiang; Hongliang Li
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

4.  High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors.

Authors:  Jianzhong Zhu; Kevin Smith; Paishiun N Hsieh; Yvonne K Mburu; Saurabh Chattopadhyay; Ganes C Sen; Saumendra N Sarkar
Journal:  J Immunol       Date:  2010-04-09       Impact factor: 5.422

5.  Endogenous Protection from Ischemic Brain Injury by Preconditioned Monocytes.

Authors:  Lidia Garcia-Bonilla; David Brea; Corinne Benakis; Diane A Lane; Michelle Murphy; Jamie Moore; Gianfranco Racchumi; Xinran Jiang; Costantino Iadecola; Josef Anrather
Journal:  J Neurosci       Date:  2018-06-26       Impact factor: 6.167

6.  Long-lasting protection in brain trauma by endotoxin preconditioning.

Authors:  Luca Longhi; Raffaella Gesuete; Carlo Perego; Fabrizio Ortolano; Noemi Sacchi; Pia Villa; Nino Stocchetti; Maria-Grazia De Simoni
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-06       Impact factor: 6.200

Review 7.  Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 8.  Targeting TLR/IL-1R signalling in human diseases.

Authors:  Maria Loiarro; Vito Ruggiero; Claudio Sette
Journal:  Mediators Inflamm       Date:  2010-04-08       Impact factor: 4.711

9.  Correction to: Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

10.  Toll-like receptor 3 agonist Poly I:C protects against simulated cerebral ischemia in vitro and in vivo.

Authors:  Lin-na Pan; Wei Zhu; Cai Li; Xu-lin Xu; Lian-jun Guo; Qing Lu
Journal:  Acta Pharmacol Sin       Date:  2012-09-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.